157 related articles for article (PubMed ID: 33594702)
1. Tumour markers with clinically controlled cut-offs for suspected cancer.
Bosch X; Molina R; Marrades R; Augé JM; Pellicé M; López-Soto A
Eur J Clin Invest; 2021 Jul; 51(7):e13523. PubMed ID: 33594702
[TBL] [Abstract][Full Text] [Related]
2. Assessment of a Combined Panel of Six Serum Tumor Markers for Lung Cancer.
Molina R; Marrades RM; Augé JM; Escudero JM; Viñolas N; Reguart N; Ramirez J; Filella X; Molins L; Agustí A
Am J Respir Crit Care Med; 2016 Feb; 193(4):427-37. PubMed ID: 26465739
[TBL] [Abstract][Full Text] [Related]
3. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
[TBL] [Abstract][Full Text] [Related]
4. Carbohydrate antigens as potential biomarkers for the malignancy in patients with idiopathic deep venous thrombosis: a retrospective cohort study.
Yu M; Wang YH; Abdalla AME; Liu WQ; Mei F; Wang J; Ouyang CX; Li YQ
J Huazhong Univ Sci Technolog Med Sci; 2014 Oct; 34(5):722-728. PubMed ID: 25318883
[TBL] [Abstract][Full Text] [Related]
5. A system for tumor heterogeneity evaluation and diagnosis based on tumor markers measured routinely in the laboratory.
Hui L; Rixv L; Xiuying Z
Clin Biochem; 2015 Dec; 48(18):1241-5. PubMed ID: 26216289
[TBL] [Abstract][Full Text] [Related]
6. Identifying the Best Marker Combination in CEA, CA125, CY211, NSE, and SCC for Lung Cancer Screening by Combining ROC Curve and Logistic Regression Analyses: Is It Feasible?
Yang Q; Zhang P; Wu R; Lu K; Zhou H
Dis Markers; 2018; 2018():2082840. PubMed ID: 30364165
[TBL] [Abstract][Full Text] [Related]
7. The reference intervals for CA125, CA15-3, CA19-9, CA72-4, AFP, CEA, NSE and CYFRA21-1.
Yang J; Tang A; Ma J; Sun X; Ming L
Scand J Clin Lab Invest; 2019; 79(1-2):71-74. PubMed ID: 30727773
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of conventional tumor markers in young patients with pulmonary nodules.
Xu L; Su Z; Xie B
J Clin Lab Anal; 2021 Sep; 35(9):e23912. PubMed ID: 34296781
[TBL] [Abstract][Full Text] [Related]
9. [Use of tumor markers in patients on chronic hemodialysis].
Kuno T; Kaizu K
Nihon Rinsho; 2004 Jun; 62 Suppl 6():391-4. PubMed ID: 15250332
[No Abstract] [Full Text] [Related]
10. Diagnostic value of tumour markers in pleural effusions.
Volarić D; Flego V; Žauhar G; Bulat-Kardum L
Biochem Med (Zagreb); 2018 Feb; 28(1):010706. PubMed ID: 29472801
[TBL] [Abstract][Full Text] [Related]
11. New and old biomarkers in the differential diagnosis of lung cancer: Pro-gastrin-releasing peptide in comparison with neuron-specific enolase, carcinoembryonic antigen, and CYFRA 21-1.
Mauro C; Passerini R; Spaggiari L; Galetta D; Radice D; Lentati P; Sandri MT
Int J Biol Markers; 2019 Jun; 34(2):163-167. PubMed ID: 30994045
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic values of SCC, CEA, Cyfra21-1 and NSE for lung cancer in patients with suspicious pulmonary masses: a single center analysis.
Chu XY; Hou XB; Song WA; Xue ZQ; Wang B; Zhang LB
Cancer Biol Ther; 2011 Jun; 11(12):995-1000. PubMed ID: 21483235
[TBL] [Abstract][Full Text] [Related]
13. The diagnostic value of the combination of carcinoembryonic antigen, squamous cell carcinoma-related antigen, CYFRA 21-1, neuron-specific enolase, tissue polypeptide antigen, and progastrin-releasing peptide in small cell lung cancer discrimination.
Chen Z; Liu X; Shang X; Qi K; Zhang S
Int J Biol Markers; 2021 Dec; 36(4):36-44. PubMed ID: 34709098
[TBL] [Abstract][Full Text] [Related]
14. [The diagnostic significance of single or combination lung cancer-related serum biomarkers in high risk lung cancer patients].
Ni J; Guo Z; Zhang L
Zhonghua Nei Ke Za Zhi; 2016 Jan; 55(1):25-30. PubMed ID: 26796649
[TBL] [Abstract][Full Text] [Related]
15. An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions.
Seemann MD; Beinert T; Fürst H; Fink U
Lung Cancer; 1999 Dec; 26(3):149-55. PubMed ID: 10598925
[TBL] [Abstract][Full Text] [Related]
16. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
17. Cancers Screening in an Asymptomatic Population by Using Multiple Tumour Markers.
Wang HY; Hsieh CH; Wen CN; Wen YH; Chen CH; Lu JJ
PLoS One; 2016; 11(6):e0158285. PubMed ID: 27355357
[TBL] [Abstract][Full Text] [Related]
18. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
19. Role of a serum-based biomarker panel in the early diagnosis of lung cancer for a cohort of high-risk patients.
Yang DW; Zhang Y; Hong QY; Hu J; Li C; Pan BS; Wang Q; Ding FH; Ou JX; Liu FL; Zhang D; Zhou JB; Song YL; Bai CX
Cancer; 2015 Sep; 121 Suppl 17():3113-21. PubMed ID: 26331818
[TBL] [Abstract][Full Text] [Related]
20. Acquired renal cystic disease and tumor markers in chronic hemodialysis patients.
Polenakovic M; Sikole A; Dzikova S; Polenakovic B; Gelev S
Int J Artif Organs; 1997 Feb; 20(2):96-100. PubMed ID: 9093887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
